Metabolomics: Technologies and Global Markets

Report Highlights

The global metabolomics market should reach $22.7 billion by 2026 from $12.7 billion in 2021 at a compound annual growth rate (CAGR) of 12.3% for the forecast period of 2021 to 2026.

Report Includes

• 59 tables
• An overview and industry analysis of the global markets for metabolomics technologies
• Analyses of global market trends, with data from 2019 to 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
• Assessment of the key marketed products and recent product launches, regulatory landscape across different demographics covering North America, Europe, Asia-Pacific, Latin America and Middle East
• Coverage of history and pathways of metabolomics, information on metabolomes and their sources like large bowel microflora, urine metabolome, food metabolome and comparison between lipidomes and lipidomics
• Highlights of the market potential for metabolomics market by product, indication, application, and region; assessment of investment in metabolomic research and spending in pharmaceutical and biotech R&D
• Information on targeted and untargeted approaches for metabolomic technology and complexity associated with data examination and processing
• Identification of leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
• Detailed profiles of the leading companies in the metabolomics market, including Agilent Technologies, Bio-Rad, Danaher Corp., Merck KGaA, Promega Corp. and Thermo Fisher Scientific

Report Scope

This report examines the current and forecasted market potential for metabolomics. It offers a detailed analysis of the market background, technological advancement, competitive environment, drivers and restraints, and market growth trends. This report includes market projections through 2026, detailing the market share for metabolomics based on product, indication and application type.

By product, the metabolomics market is segmented into separation techniques, detection techniques, assays, and bioinformatics. By indication type, the metabolomics market is segmented into cancer, cardiovascular disorders, neurological disorders, inborn errors of metabolism, and others. The others segment covers respiratory diseases, infectious diseases, etc. By application, the metabolomics market is segmented into biomarker discovery, drug discovery, toxicology testing, nutrigenomics, functional genomics, and others.

By geography, the metabolomics market has been segmented into Europe, North America, Asia-Pacific (APAC), Latin America, and the Middle East & Africa (MEA). The detailed analyses of major countries such as the U.S., Germany, Canada, the U.K., Spain, Italy, France, Japan, India, and China are found in the regional segments. For market estimates, data is provided for 2020 as the base year, for 2021 and forecast through year-end 2026. Estimated values used are based on metabolomics companies’ total revenues. Projected and forecast revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.